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AKTIVITI SITOTOKSIK DAN MEKANISME-MEKANISME TINDAKAN 
EKSTRAK-EKSTRAK CRINUM ASIATICUM KE ATAS PELBAGAI 
TITISAN SEL KANSER 
ABSTRAK 
Crinum asiaticum yang dikenali oleh penduduk tempatan sebagai tembaga 
suasa, digunakan dalam perubatan tradisional, untuk merawat inflamasi/bengkak dan 
tumor. Beberapa kandungan kimianya telah diasingkan dan didapati mempunyai 
kesan anti-tumor, termasuk likorin. Tujuan penyelidikan ini ialah untuk mengkaji 
aktiviti sitotoksik (sitotoksisiti) dan mekanisme tindakan, tumbuhan spesis Malaysia 
ini, ke atas pelbagai titisan sel kanser. Ekstrak-ekstrak methanol akar, ubi, batang dan 
daun, difraksikan lagi dengan menggunakan heksana, dietil eter, butanol dan air 
suling. Kesemua ekstrak diuji dengan menggunakan assai MTT, ke atas tiga titisan 
sel kanser manusia (3 daripada 4 kanser yang membentuk 50% kematian akibat 
kanser): Hep-2 (kanser larynx), HCT-116 (tumor kolorektal manusia) dan MCF-7 
(kanser payudara); dan dua titisan sel normal: Vero (medula ginjal monyet hijau 
Afrika) dan EAhy-926 (hibrid sel-sel endotelial dan kanser paru-paru manusia). 
Ujian lanjutan telah dijalankan untuk membandingkan sitotoksisiti fraksi-fraksi 
ekstrak ke atas sel-sel Vero dan Hep-2. Kesan anti-angiogenik juga telah dikaji, 
menggunakan assai bulatan aorta tikus, migrasi sel dan pengeluaran VEGF manusia 
dalam sel-sel EAhy-926. Mekanisma tindakan sitotoksisiti kemudian telah dikaji, 
melalui kajian klonogenisiti, kondensasi nuklear, perubahan potensi membran 
mitokondria dan kesan-kesan ke atas 10 laluan major kanser iaitu, wnt (TCF/LEF), 
notch (RBP-Jκ), p53/kerosakan DNA, TGFβ (SMAD2/3/4), putaran sel/pRb-E2F 
(E2F/DP1), NFκB, myc/Max, hipoksia (HIF1α), MAPK/ERK (Elk-1/SRF) dan 
MAPK/JNK (AP-1). Ekstrak metanol daun C. asiaticum (CALME) menunjukkan 
xviii 
 
sitotoksisiti yang signifikan ke atas sel Vero, sementara ekstrak-ekstrak metanol lain 
tidak menunjukkan kesan signifikan. Tiada perbezaan sitotoksisiti yang signifikan di 
antara pelbagai ekstrak, yang diambil daripada bahagian-bahagian pokok yang 
berlainan, dan juga, fraksi-fraksi ekstrak. CALME menunjukkan kesan sitotoksik 
aktif ke atas semua sel-sel yg terpilih, kecuali sel Vero (kesan sitotoksik sederhana). 
Nilai ‘IC50’ yang diperolehi adalah di antara 4.15 dan 46.88 µg/ml. Ekstrak juga 
menunjukkan selektiviti tinggi untuk MCF-7 dan HEP-2, berbanding dengan VERO, 
dan hampir selektif untuk MCF-7, berbanding dengan EAhy-926. Kajian 
klonogenisiti ke atas sel-sel MCF-7 menunjukkan CALME adalah sitotoksik, dan 
bukan sitostatik. Perubahan-perubahan morphologi apoptotik lewat dalam sel juga 
dikesan; CALME menyebabkan kondensasi DNA dan gangguan potensi membran 
mitokondria. CALME telah didapati menyebabkan apoptosis dalam sel-sel MCF-7, 
samada melalui pengawalaturan menurun gene-gene pro-proliferatif (hipoksia dan 
MAPK/JNK), atau melalui pengawalaturan menaik gene-gene perencat tumor (p53, 
TGF-β, pRb-E2F, and NF-κB). Kajian ini mendapati bahawa CALME merencat 
pertumbuhan saluran darah baru, dan oleh itu, menunjukkan kesan anti-angiogenik. 
Perencatan migrasi sel dan produksi VEGF oleh ekstrak ini, juga menyokong aktiviti 
anti-angiogeniknya. Walaubagaimanapun, aktiviti anti-tumor CALME adalah 
disebabkan oleh sitotoksisiti, bukan aktiviti anti-angiogenik. Keputusan-keputusan 
spektra mengesahkan kehadiran alkaloid aktif likorin dalam ekstrak daun tempatan, 
seperti yang terdapat dalam spesis dari India. Keputusan-keputusan kajian ini jelas 
menunjukkan potensi anti-kanser CALME terhadap kanser payudara.  
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CYTOTOXIC ACTIVITY AND MECHANISMS OF ACTION OF CRINUM 
ASIATICUM  EXTRACTS ON VARIOUS CANCER CELL LINES 
ABSTRACT 
Crinum asiaticum, locally known as ‘tembaga suasa’, is used traditionally to 
treat inflammations and tumours. Several chemical constituents had been isolated 
and found to have anti-tumour property, including lycorine. This study aims to 
investigate the cytotoxic activity (cytotoxicity) and mechanisms of action of the 
Malaysian species plant, on various cancer cell lines. The methanol extracts of the 
root, bulb, stem and leaf were further fractionated using hexane, diethyl ether, 
butanol and distilled water. All extracts were screened, using MTT assay, against 
three human cancer cell lines (3 of 4 cancers that form 50% cancer deaths): Hep-2 
(laryngeal carcinoma), HCT-116 (human colorectal tumour) and MCF-7 (breast 
cancer); and two normal cell lines: Vero (African green monkey kidney medulla) and 
EAhy-926 (hybrid of human endothelial and lung cancer cells). Further tests were 
performed to compare the cytotoxicity of extract fractions on Vero and Hep-2 cells. 
The anti-angiogenic effect was also studied, using rat aorta ring assay, migration and 
human VEGF production in EAhy-926 cells. The mechanisms of cytotoxicity were 
then studied, by clonogenicity study, determination of nuclear condensation, 
mitochondrial membrane potential changes, and the effects on 10-major cancer 
pathways, wnt(TCF/LEF), notch(RBP-Jκ), p53/DNA damage(p53), 
TGFβ(SMAD2/3/4), cell cycle/pRb-E2F(E2F/DP1), NFκB, myc/Max, 
hypoxia(HIF1A), MAPK/ERK(Elk-1/SRF) and MAPK/JNK(AP-1). C. asiaticum 
leaf methanol extract (CALME) showed significant cytotoxicity against Vero cells, 
while the other methanol extracts did not show significant effects. There was no 
significant difference between the cytotoxicity of extracts taken from different parts 
xx 
 
of the plant, and also extract fractions. CALME showed active cytotoxicity on all 
selected cell lines except for Vero (moderately cytotoxic). IC50 values obtained 
ranged from 4.15 to 46.88 µg/ml. The extract also showed high selectivity for MCF-
7 and HEP-2, compared to VERO, and marginally selective for MCF-7, compared to 
EAhy-926. The clonogenicity study on MCF-7 cells indicated CALME to be 
cytotoxic, and not cytostatic. The late apoptotic morphological changes in cells were 
also detected; CALME caused DNA condensation and disrupted mitochondrial 
membrane potential. CALME was found to induce apoptosis in MCF-7 cells, either 
by down-regulating pro-proliferative genes (hypoxia and MAPK/JNK), or by up-
regulating tumour suppressor genes (p53, TGF-β, pRb-E2F, and NF-κB). Thus, the 
main mechanism of action for cytotoxicity is apoptosis via the mentioned pathways. 
This study also found that CALME inhibited new blood vessel growth, thus, 
exhibiting anti-angiogenic effect. The cell migration and VEGF production inhibition 
by CALME further support its anti-angiogenic activity. However, the anti-tumour 
activity of CALME is due to cytotoxicity, not anti-angiogenic activity. The spectral 
results confirmed the presence of the active alkaloid lycorine in the local leaf extract, 
as found in the Indian species. The results of this study clearly highlight the anti-
cancer potential of CALME towards breast cancer. 
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CHAPTER 1: INTRODUCTION  
1.1 Cancer  
Billions of dollars have been spent on cancer research and yet we do not understand exactly 
what cancer is. It has been difficult to develop an accurate definition for cancer. The reputed 
British oncologist Willis has defined cancer as “an abnormal mass of tissue, the growth of 
which exceeds and is uncoordinated with that of the normal tissues, and persists in the same 
excessive manner after cessation of the stimuli which evoked the change” (Cotran et al., 
1999). Cancer is the abnormal growth of cells in our bodies that can lead to death. It is a 
group of more than 100 different diseases, which are characterized by uncontrolled cellular 
growth, local tissue invasion and distant metastasis (Chabner, 2006). 
 
The mechanisms by which cancer arises are incompletely understood. The cancer is assumed 
to develop from cells in which the typical managing mechanisms of the cells‟ proliferation 
and growth have been altered. Recent proofs strengthen the notion of carcinogenesis as a 
genetically regulated multistage process. The first step in this process is „initiation‟ which 
starts by exposure of cells to carcinogenic substances which lead to genetic damage that, if 
not repaired, results in irreversible mutations. The mutated cells grow till formation of a 
colony. The second stage is „promotion‟, in which carcinogens or other factors modify the 
environment, in a way which supports growth of mutated cells over normal cells (Mediana 
and Fausel, 2008). The next stage is „transformation‟ of mutated cells to cancerous cells; 
about 5 to 20 years may be required for the transition of benign carcinogenic phase to the 
fully developed malignant stage, where the cancer can be detected clinically. The last stage 
called „progression‟, where further genetic changes take place, leading to increase in the 
proliferation and metastasis (Weinberg, 1996, Compagni and Christofori, 2000).  
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1.1.1 Cancer Epidemiology  
Every year, millions of people are diagnosed with cancer, leading to death. It is estimated 
that almost 1.7 million new cases of cancer will be diagnosed in 2017. Prostate cancer is the 
most common cancer among males (19%), followed by lung (14%) and colorectal (9%) 
cancers. Among females, breast (30%), lung (12%), and colorectal (8%) cancers are the most 
common (American Cancer Society, 2017).  
In Malaysia, cancer was the number 4 killer in the year 2002. However, in the year 2014, it 
became the number 1 killer (Ministry of Health Malaysia, 2014). Worldwide now, it is also 
the most lethal among all types of diseases (World Health Organization, 2014).  
Lung cancer is by far the leading cause of cancer death among males (27%), followed by 
colorectal (9%) and prostate (8%) cancers. Among females, lung (25%), breast (14%), and 
colorectal (8%) cancers are the leading causes of cancer death (American Cancer Society, 
2017). Thus, cancers of the lung and bronchus, prostate, and colorectal in men, and cancers 
of the lung and bronchus, breast, and colorectal in women, form about 50% of cancer deaths 
among men and women.  
The 5-year survival rates have been increased as new drugs and treatment approaches have 
been introduced; in 1930s, only 20% of cancer patients survived five years or more after 
treatment. In 1940s the survival rates increased to 25%. During the 1960s, the 5-year survival 
rate was 33%, and in the 1970s it was 38%. Between years 2000 to 2005, 51% of cancer 
patients survived for five years or more (Rodriguez and Case, 2005).   
However, while the survival rate increases, the incidence and mortality rate also keep on 
growing (Parkin, 2001). This contradiction between increasing of the 5-years‟ survival rate 
and the worldwide death rate due to cancer, can be explained by increased life anticipation, 
since cancer incidence increases with age (Ries et al., 2000, Jemal et al., 2009).  
 
3 
 
1.1.2  Genetic and Molecular Basis of Cancer  
Developing cancer cells select mutations having two basic functions: mutations which 
increase the activity of the proteins they code for, or mutations which inactivate gene 
function. The gene whose activity increases by mutation, is called oncogene, while that 
inactivated by mutation, is called tumour suppressor gene.   
Oncogenes are involved in signalling pathways which stimulate proliferation, while human 
suppressor genes code for proteins which normally act as checkpoints to cell proliferation. 
These alterations occur by carcinogenic agents like radiation, chemicals or viruses (somatic 
mutations), or they may be inherited (germ-line mutation) (Croce, 2008, Bertram, 2000, 
Mediana and Fausel, 2008, Yarbro et al., 2005).  
Six major pathways must be activated or inactivated in the genes of normal cells to convert 
to cancerous cells; these are:  
i. development of independence in growth stimulatory signals  e.g., activation of a 
family of oncogenes called human epidermal growth factor receptor (Hanahan and 
Weinberg, 2000), 
ii.  development of a refractory state to growth inhibitory signals e.g., mutations in 
suppressor genes p53 (Feng et al., 2008),  
iii. development of resistance to programmed cell death e.g., over expression of Bcl-2 
genes (Kroemer, 1997),  
iv. development of an infinite proliferative capacity e.g., over expression of telomeras 
enzyme (Holt and Shay, 1999),  
v. development of angiogenic potential i.e., the capacity to form new blood vessels and 
capillaries e.g., over expression of VEGF (Folkman, 1995), and  
vi. tissue invasion and metastasis e.g., over expression of Myc oncogenes (Kawashima 
et al., 1988).  
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1.1.3  Cell Death and Apoptosis  
Cell death is a key event in biology. Cells die via two main processes; either necrosis or 
apoptosis (programmed cell death) (Kerr et al., 1972). Apoptosis is firmly regulated by 
complex molecular signalling systems. Apoptosis plays a key role in development, 
morphogenesis, tissue remodelling and disposing of aged or damaged cells. The initial 
definition of apoptosis was morphological: Dying cells exhibit a characteristic pattern of 
changes, including cytoplasmic shrinkage, active membrane blebbing, chromatin 
condensation, and, typically, fragmentation into membrane-enclosed vesicles (apoptotic 
bodies) (Wyllie et al., 1980). In this process the cells activate an intracellular death 
programme and kill themselves in a controlled way. Because apoptotic cells shrink during 
this process, they are rapidly digested, thus, there are no leakages of their contents (Raff, 
1998).  
In contrast, necrosis is a term that describes uncontrolled process in which death takes place 
after exposure to an acute injury. The cells swell and burst, spilling their content over the 
surrounding tissue and cause inflammation (Raff, 1998). Any change in apoptosis rate in the 
body, either increasing or decreasing may cause many diseases. Apoptosis hyper-activation 
associated with neurodegenerative diseases (e.g., Parkinson‟s and Alzheimer‟s syndromes), 
hematologic diseases (e.g., aplastic anaemia and lymphocytopenia) and disease characterized 
with tissue damage (e.g., myocardial infarction). On the other hand, increasing cell survival 
via apoptosis inhibition is related to autoimmunity diseases (e.g., systemic lupus 
erythematosus) and tumour growths (Chamond et al., 1999).  
Studies of tumour growth kinetics showed that changes in cell loss factors, have influence on 
tumour growth or regression. Further studies revealed a high rate of apoptosis occurrence in 
tumours treated with cytotoxic agents that regressed after treatment (Kerr et al., 1972).   
Apoptosis can be induced through a number of pathways by proteins that control the cell 
cycle machinery including p53, Wnt, hypoxia, NF-қB, Notch and MAPKs pathways 
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(Ghobrial et al., 2005). Any defects in these regulatory pathways have been related to many 
malignancies (Kaufmann and Hengartner, 2001).  
1.1.4  Apoptosis Pathways  
Apoptotic signalling events can be divided into two major pathways based on the mechanism 
of initiation: the intrinsic pathway which mainly depends on mitochondrial changes, and the 
extrinsic pathway which is activated via death receptors. Although different molecules take 
part in the core machinery of both apoptosis signalling pathways, a crosstalk exists at 
multiple levels (Ghobrial et al., 2005). 
1.1.5 Signal Transduction Pathways in Cancer:  
Cancer cells have the ability to change the surrounding environment in a way that will assist 
them to grow and proliferate. They respond to any internal or external circumstances by 
increasing or decreasing the expression of proteins which can adjust the situations in favour 
of increasing the proliferative, invasive and metastatic properties (Hanahan and Weinberg, 
2000). The reciprocal communications between the external or internal circumstances and 
protein expression level take place via activation of a cascade of intracellular biochemical 
reactions which is also called signal transduction pathways (Lobbezoo et al., 2003). Each 
pathway starts with ligation of extracellular receptors. The receptor activation is translated 
into biological response by activation of proteins (transcriptional factors) which then 
translocate into the nucleus and bind with the DNA in specific binding sites (promoters) and 
trigger the transcription of mRNAs which later translated to proteins (Eccleston and Dhand, 
2006).  
Oncogenic gene mutations results in a constitutive activation of signal transduction elements, 
simulating a condition of permanent activation of the receptor, even in the absence of the 
relevant growth factor (Hanahan and Folkman, 1996). Wnt, Notch, TGF-β, Myc/Max, 
Hypoxia, MAPK pathways were reported to be hyper-activated in cancerous cells (Clevers, 
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2004, Miyazawa et al., 2002, Fang and Richardson, 2005, Soucek et al., 2008, van Es and 
Clevers, 2005a).  
On the other hand, mutations in tumour suppressor genes lead to deactivation of some 
pathways which may serve as checkpoints of cell proliferation such as p53 (Feng et al., 
2008). These pathways can be targeted with signal transduction modulators (STMs) in order 
to treat cancer. The STMs can modulate the pathway activity at many levels such as blocking 
cell surface receptors, blocking the mediators between extracellular signals and the 
transcriptional factor, deactivate the binding between the transcriptional factors with the 
promoters or inhibiting the effects of further downstream genes (Lobbezoo et al., 2003).  
STMs have attracted attention of many researchers. Many STM compounds are being 
investigated in preclinical studies or in clinical trials. Additionally, there are two approved 
STM drugs which have been commercially marketed; trastuzumab and imatinib (Lobbezoo et 
al., 2003). 
1.1.6 Angiogenesis  
Angiogenesis is a process of new blood vessel development. It occurs in the healthy body for 
healing wounds and for restoring blood flow to tissues after injury or insult. The healthy 
body controls angiogenesis through a series of "on" and "off" switches. When angiogenic 
growth factors are produced in excess of angiogenesis inhibitors, the balance is tipped in 
favour of blood vessel growth. When inhibitors are present in excess of stimulators, 
angiogenesis is stopped. The normal, healthy body maintains a perfect balance of 
angiogenesis modulators. In general, angiogenesis is "turned off" by the production of more 
inhibitors than stimulators. In many serious disease states, the body loses control over 
angiogenesis (Harris, 1997).  
Angiogenesis-dependent diseases result when new blood vessels either grow excessively or 
insufficiently. Angiogenesis plays an important role in many diseases, such as cancer, 
rheumatoid arthritis, and diabetic retinopathy (Carmeliet, 2005, Folkman, 1995). Drugs that 
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modulate, inhibit or stimulate angiogenesis, can be useful to treat a variety of diseases that 
stem from angiogenesis dysfunction.  
In cancer, angiogenesis plays an important role in tumour growth, without which, neoplastic 
tissues will be unable to expand beyond 1 to 2 mm
3 
(Folkman and Cotran, 1976). Cancer 
cells within the tumour can also use the newly formed blood vessels as a port to metastasize 
to other localities (Weidner et al., 1991). Since the interdependency and a close relationship 
between angiogenesis, cancer growth and metastasis has been well-established, much efforts 
have been invested into development or discovery of anti-angiogenic compounds, to treat 
cancer and a variety of other angiogenic related ailments.  
1.1.6 (a) The Vascular Endothelial Growth Factor (VEGF)  
As the size of the tumour increases, oxygen demand increases, causing a state of hypoxia (Fu 
et al., 1976). The hypoxic state in the tumour spring forth oxygen free radicals, which in turn 
activates vascular endothelial growth factor (VEGF) triggering the angiogenesis event 
(Mukhopadhyay et al., 1995). VEGF (referred to also as VEGF-A) is regarded as a heparin 
binding angiogenic growth factor exhibiting high specificity for endothelial cells 
(Gospodarowicz et al., 1989). VEGF is responsible for triggering various steps in the 
angiogenesis cascade such as proliferation, migration and cell survival (Ferrara, 2002). The 
tumour regression and inhibition can be achieved by deactivating VEGF activity via 
neutralizing antibodies or by introduction of dominant negative VEGF receptors (Kim et al., 
1993). The VEGF protein and RNA levels are significantly upregulated in most types of 
cancer. The high concentration of VEGF in cancer patients is associated with poor prognosis 
(Paley et al., 1997).   
1.1.6 (b) Angiogenesis Process Cascade  
Angiogenesis is a sophisticated multistep process. Increasing of VEGF-165 expression is 
crucial in initiating the angiogenesis process (Nagy et al., 2003). Angiogenesis starts with 
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dilatation of blood vessels to increase the permeability to the angiogenesis signals. Then, the 
pericytes which cover the blood vessels, detach and the vascular basement membrane and 
extracellular matrix get degraded, which allow for the underlying endothelial cells to migrate 
into the perivascular space towards chemotactic angiogenic stimuli (Ko et al., 2007). The 
migrated endothelial cells proliferate, loosely following each other into the perivascular 
space and form migration columns. Then, the endothelial cells differentiate; cells‟ shape 
change in a way that facilitates the cell-cell adherence which then forms a lumen (tube-like 
structure). Perivascular cells are attracted, and a vascular basal lamina is produced around the 
newly formed vessels. The details are still vastly obscure for the last stages when vascular 
sprouts fuse with other sprouts to form loops (Bergers and Benjamin, 2003, Carmeliet, 2005).  
1.1.6 (c) Cancer is Angiogenesis Dependent  
Many studies have confirmed the hypothesis that tumour growth is reliant on 
neovascularisation process. Any significant increment in tumour size must be in synchrony 
with increment in the blood supply and blood vessels size (Folkman, 1990). The hypothesis 
was confirmed by many experimental evidences. In one study, tumours implanted in places 
where there is no probability of new blood vessels to grow such as the aqueous fluid of the 
anterior chamber of the eye remained viable, avascular, and limited in size (<1 mm
3
). When 
the cells were implanted on iris vessels, they induced new blood vessels formation which 
grew hastily reaching 16,000 times their original size within two weeks (Gimbrone et al., 
1972). Another evidence that strengthened this hypothesis was the detection of exponential 
and rapid growth of tumours that were implanted on the chorioallantoic membrane of the 
chick embryo after blood vessels formation (Knighton et al., 1977). Studies on 
subcutaneously implanted tumours showed that the blood vessels form approximately 1.5% 
of the tumour volume; this number represents 400% increase over normal subcutaneous 
tissue (Thompson et al., 1987). 
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1.1.6 (d) The Angiogenic Switch  
It takes between five to twenty years for the transition from benign carcinogenic phase to the 
fully developed malignant stage where the cancer can be perceived clinically (Mediana and 
Fausel, 2008). Dormancy stage occurs when tumour cells proliferate but the rate of tumour 
cell death (apoptosis) counterbalances this proliferation and maintains the tumour mass in a 
steady state (Ribatti et al., 1997). At this stage, there is a balance between two contrary 
signals; angiogenesis signals like VEGF (Ferrara et al., 2003) and anti-angiogenesis signals 
(e.g., endostatin, angiostatin) (Kim et al., 2000). Therefore, the angiogenesis process starts 
only when the net balance between these contrary signals is tipped in favour of angiogenesis 
initiation (Hanahan and Weinberg, 2000, Hanahan and Folkman, 1996).  
Accordingly, identification and interrupting of the factors and the circumstances which 
increase the probability of angiogenesis initiation may keep the cancerous cells in the stage 
of dormancy (Gullino, 1978). The studies showed that angiogenesis process can be triggered 
by a variety of signals including metabolic stress (e.g., hypoxia or hypoglycaemia), 
mechanical stress (e.g., pressure generated by proliferating cells), immune/inflammatory 
response (immune/inflammatory cells that have infiltrated the tissue), and genetic mutations 
(Hanahan and Weinberg, 2000). These circumstances cause synthesis or release of 
angiogenic factors such as VEGF (Ribatti, 2009).  
1.1.6 (e) Hypoxia  
Hypoxia is defined as a decrease in the oxygen supply to a level insufficient to maintain 
cellular function. The cells become hypoxic if it is located too far away from blood vessels. 
Due to cell proliferation and tumour growth, the cells in the core of tumour, become hypoxic 
(Carmeliet, 2005). Hypoxic cells are more invasive and metastatic, and more resistant to 
chemotherapy or radiation (Melillo, 2007).  
Recent evidence demonstrated the impact of activation of hypoxia inducible transcription 
factors (HIFs) in hypoxic cells in angiogenesis process (Zhong et al., 1999). The binding of 
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HIFs to the DNA, induces expression of several angiogenic factors including VEGF, nitric 
oxide synthase, platelet-derived growth factor (PDGF), and many others (Ahmed and 
Bicknell, 2009, Carmeliet, 2005). The critical step in induction of this pathway is the 
stabilization of the HIFs. The most important two members of HIFs are HIF-1 and HIF-2.  
HIF-1 is ubiquitously expressed, while HIF-2 is expressed only in endothelial cells and in the 
kidney, heart, lungs and small intestine (Wang et al., 1995, Semenza, 2001). HIF-1 complex 
is a heterodimer consisting of two DNA binding proteins, HIF-1α and HIF-1β. The 
expression of HIF-1α is tightly regulated by oxygen, while the HIF-1β is expressed 
constitutively (Bracken et al., 2003, Wang et al., 1995). Under normoxic conditions, HIF-1α 
is rapidly degraded due to enzymatic prolylhydroxylation. However, under hypoxic 
conditions the stability and half-life of HIF-1α increased remarkably. Accordingly, HIF-1α 
dimerizes with HIF-1β. The heterodimer is then translocated to the nucleus and activates the 
promoter region of target genes (Wang et al., 1995).  
As the expression of the chief factor in the angiogenesis, VEGF, and many angiogenic 
pathways is related directly with the activation of HIF-1, the search for drugs targeting HIF is 
currently receiving a lot of attention (Semenza, 2003). The notion of targeting HIFs to treat 
cancer was proven experimentally by a study that showed that tumour growth was reduced 
significantly in mice implanted with cells infected with a polypeptide which disrupted the 
binding of HIF-1α to its transcriptional co-activators (Kung et al., 2000). Several approaches 
targeting tumour hypoxia have been proposed, including prodrugs activated by hypoxia, 
hypoxia-selective gene therapy and the use of recombinant obligate anaerobic bacteria 
(Brown and Wilson, 2004). Besides, the mechanism of action for some anti-angiogenic 
natural compounds such as betulinic acid, Klugine, isocephaeline, emetine and taxol has been 
confirmed to involve hypoxia pathway inhibition (Karna et al., 2010, Fan et al., 2006, Zhou 
et al., 2005). 
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1.1.6 (f) Anti-angiogenesis Targets  
Agents that suppress or stop neovascularisation often do so by interfering with an 
essential step in this process, such as: (i) inhibition of endothelial cells activation which may 
be achieved via inhibition of growth factor signal production, inhibition of receptors 
production and / or inhibits the binding between signals and receptors, (ii) inhibition of 
endothelial cells proliferation, (ii) inhibition of endothelial cells migration, (iv) inhibition of 
endothelial cells differentiation to form a three dimensional tube-like structure and (v) 
induction of apoptosis in endothelial cells (Zhang and Bicknell, 2001).  
1.1.6 (g) Pros and Cons of Angiogenesis Treatment 
The main difference between the cytotoxic chemotherapy and anti-angiogenic 
therapy is the target; the chemotherapy agents target tumour cells itself, but antiangiogenic 
compounds target the endothelial cells. Accordingly, anti-angiogenic compounds gained 
many advantages over conventional cytotoxic agents; endothelial cells are highly genetically 
stable with low mutation rate, thus the probability to develop resistance against anti-
angiogenesis agents is very low compared to cytotoxic agents (Folkman, 2003). Moreover, 
little or no toxicity is associated with anti-angiogenic therapy. This advantage is expected as 
anti-angiogenic compounds target specific immature characteristics of tumour vasculature 
(Kerbel, 2000).  
Another important advantage is that endothelial cells are highly accessible to therapeutic 
agents, because the endothelial cells are directly exposed to blood borne substances 
(Schliemann and Neri, 2007). Nevertheless, anti-angiogenic compounds possess some 
drawbacks; they also interrupt normal physiological neovascularisation process such as 
pregnancy, wound healing, children growth and also likely to be responsible in inducing 
amenorrhea (D'Amato et al., 1994). However, many experts strongly believe that these 
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mentioned threats of the anti-angiogenic drugs are exceptionally low. The anti-angiogenic 
drug regime can be halted in patients with wounds or utilization of a topical angiogenesis-
inducing agent may be employed; so as not to perturb the wound healing progress.  
The use of anti-angiogenic agents in young patients has also turned out to be safe given that 
the major fraction of the angiogenesis process that occurs during development stages has 
ceased. Therefore, the opposing effects of the drugs are considered to be insignificant. The 
notion that the anti-angiogenic drugs may thwart pregnancy as well as inducing amenorrhea, 
are in fact advantageous, considering these factors are not favoured in patients undergoing 
the anti-angiogenic drug treatment (Zhang and Bicknell, 2001).  
 
1.1.7 Natural Products and Cancer Treatment 
Some secondary metabolites of plants such as alkaloids, terpenoids and glycosides, 
serve either as protective agents against various pathogens (e.g., insects, fungi or bacteria) or 
growth regulatory molecules (e.g., hormone-like substances). As a result, secondary 
metabolites can serve as potential anti-cancer drugs, either by direct cytotoxic activity against 
cancer cells, or by modulating the tumour development process (Kintzios, 2003). 
   
1.2 Traditional Medicine 
1.2.1 Plants in medicine 
Of all the plants found to have medicinal uses, none are more welcomed than those 
that aid in our fight against cancer. Thousands of lives have been saved or extended, by the 
alkaloids, vincristine and vinblastine of the Madagascaran annual periwinkle. The success of 
using these compounds in combination chemotherapy for treating Hodgkin‟s disease (80% 
remission), acute lymphocytic leukaemia (99% remission), Wilms‟ tumour (80% cured), 
Burkitt‟s lymphoma (50% cured), and gestational choriocarcinoma (70% cured) are 
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testimonials to the monumental strides achieved in the past, when plant products have been 
introduced against the most dreaded of all diseases (Lewis & Elvin, 1977). Further 
experimentation has indicated that mixtures of the alkaloids with other chemicals may 
produce even better results (Brintnall, 1986). 
Over 50% of conventional drugs in clinical use are of natural products, many of which can 
control cancer cells. According to the WHO, more than 80% of people in developing 
countries depend on traditional medicine for their primary health needs. A recent survey 
shows that over 60% of cancer patients use vitamins or herbs as therapy. Continuous usage 
of herbal medicine by majority of the population in the developing countries is mainly due to 
the high cost of western pharmaceuticals and healthcare. In addition, herbal medicines are 
more acceptable in these countries from their cultural and spiritual points of view. (Kaur et 
al, 2011).  
 
1.2.2 Anti-tumour agents isolated from plants 
Cancer is one of the most feared diseases of our time. Pharmaceutical companies 
continually search for anti-cancer agents, and people afflicted with cancer, grasp at any 
possible panacea. The continued public pressure to allow the use of laetril (extracted from the 
seeds of apricot) as a treatment, despite constant documentation that it is ineffective in 
controlling cancer, indicates the desperation with which cures are sought. The search for 
truly effective anti-cancer agents has not yet been achieved. In the past few decades, a 
number of naturally occurring plant alkaloids were found to arrest cancer cells growth 
(Brintnall, 1986). 
Because many alkaloids have psychoactive properties, and some are valuable medicines, they 
have received much attention since the 1960s. More than 5000 have been named, and 
alkaloids usually exist in plants as bitter-tasting, soluble, organic acid -alkaloid salts. They 
themselves are soluble in organic solvents, but not in water. In general, alkaloid content is 
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not subjected to ecological variation, and they are usually distributed throughout the plant, 
making all parts toxic (Saigo & Barbara, 1983). 
The common periwinkle (Catharanthusroseus, Apocynaceae) has been used in its native 
range in Europe, for hundreds of years, as a folk treatment for diabetes. The plant was tested 
for effectiveness against various illnesses, because of its use in folk medicine. It was tried for 
the treatment of leukaemia in 1957, and found to be effective in curing some forms of the 
disease (especially those that commonly afflict children). The active chemicals, identified as 
vinblastine and leurocristine (vincristine) were marketed shortly after 1957, under several 
trade names.  
Another plant found to contain anti-tumour alkaloids, is the mayapple 
(Podophyllumpeltatum, Berberidaceae). Plants of this species are herbaceous perennials that 
flower early in spring, in the deciduous forests of Canada and eastern U.S. The active 
compounds podophyllin, alpha and beta peltatin, are especially abundant in the rhizomes. 
Extracts of the roots were used by native Indians as purgatives and for skin disorders and 
tumorous growths. Now, mayapple alkaloids are used as the basis of VM-26, a drug used to 
treat lymphocytic leukaemia. VM-26 appears to be as effective as vincristine, in treating 
childhood leukaemias, although newer than the drugs based on Catharanthus alkaloids 
(Brintnall, 1986). 
Finally, the plant autumn crocus (Colchicum autumnale, Liliaceae) has been used with some 
success in the treatment of cancer. The alkaloid colchicine, extracted from the corns of this 
species, interferes with mitotic cell division. Colchicine inhibits mitosis by interfering with 
development of the mitotic spindle, preventing separation of daughter chromosomes (Saigo 
& Barbara, 1983). As a chemotherapeutic agent, it makes use of this action by, hopefully, 
preventing the growth of cancer cells. However, since colchicine also affects normal cells, its 
use must be closely monitored, and it has produced only limited successful results (Brintnall, 
1986). 
15 
 
Some anti-tumour agents isolated from plants, used for treating cancer traditionally, are 
shown in Table 1.1 below (Sofowora, 1982; Kaur et al, 2011). 
 
Table 1.1: Anti-tumour agents isolated from plants, used for treating cancer traditionally. 
Sr. 
No. 
Plant name /Family Country where 
used 
Active principle Class 
1. Agapanthus africanus 
Agapanthaceae 
S. Africa 
 
Isoliquiritigenin Chalcone 
2 Aglailasylvestre 
Meliaceae 
India Silvesterol --- 
3 Ailanthus Altissima 
Simaraubaceae 
China Ailnthone, Ailantenol Quassinoids 
4 Apiumgraveolens 
Umbelliferae 
N. America Apigenin 
 
Flavonoid 
5 Bleckeriavitensis 
Apocynaceae 
France Ellipticine Alkaloid 
6 Bruceaantidysenterica 
Simaraubaceae 
Ethiopia Bruceantin Quassinoids 
7 Burseramicrophylla 
Burseraceae 
Mexico Burseran Lignan 
8 Campotheca acuminate 
Nyssaceae 
China Campothecin Alkaloid 
9 Catharanthusroseus L. 
Apocynaceae 
India, Africa  Vincristine, vinblastine, 
vindesine 
Alkaloid 
10 Centaureamontata 
Asteraceae 
Europe Montamine Alkaloid 
11 Centaureaschischkinii 
Asteraceae 
---------- Schischkinnin Alkaloid 
 
12 Cephalotaxusharringtonia 
Cephalotaxaceae 
Japan Homo-harringtonine Alkaloid 
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Table 1.1: Continued 
Sr. 
No. 
Plant name /Family Country where 
used 
Active principle Class 
13 Cephalotaxusfortune 
Cephalotaxaceae 
China  Harringtonine,  
homo-harringtonine 
Alkaloid 
14 Cleistanthuscollinus 
Euphorbiaceae 
India Cleistanthin,  
Collinusin 
Lignan 
15 Combretumcaffrum 
Combretaceae 
S. Africa Combrestatins 
 
Stilbenes 
16 Croton lechleri 
Euphorbiaceae 
S. America Taspine Alkaloid 
17 Daphne mezereum 
Thymelaeaceae 
Asia, Europe Mezerein 
 
------- 
18 Diphylleiagrayi 
Berberidaceae 
Japan Diphyllin Lignan 
19 Dysoxylumbinectariferum 
Meliaceae 
India Rohitukine Alkaloid 
20 Erythroxylumpervillei 
Erythroxylaceae 
Madagascar Pervilleine Alkaloid 
21 Euphorbia semiperfoliata 
Euphorbiaceae 
Europe Jatrophane Terpenoid 
22 Fritillariathunbergii 
Liliaceae 
China, Japan Zhebeinone Alkaloid 
23 Gunneraperpensa 
Gunneraceae 
Brazil 2-methyl-6(3-methyl 2-
butenyl) benzo1-4-
quinone 
Quinone 
24 Hypericumperforatum 
Clusiaceae 
Europe Hypericin Anthra-quinone 
25 Hypoxiscolchicifolia 
Hypoxidaceae 
S. Africa  
 
Hypoxoside, Rooperol Glycoside 
26 Heliotropiumindicum L. India Indicine-N-oxide --------- 
27 Indigoferatinctoria 
Leguminosae 
Asia Indirubins Indigoids 
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Table 1.1: Continued 
Sr. 
No. 
Plant name /Family Country where 
used 
Active principle Class 
28 Jatropha gossypiifolia L. Costa Rica Jatrophone --------- 
29 Justiciaprocumbens 
Acanthaceae 
India Justicidin A,B Lignan 
30 Lantana camara 
Verbenaceae 
America Verbascoside Glucoside 
31 Larrea tridentate  
Zygophyllaceae 
Mexico Terameprocol Lignan 
32 Linium album  
Linaceae 
--------- Podophyllotoxin Lignan 
33 Lonicera japonica  
Caprifoliaceae 
Japan Luteolin Flavanoid 
34 Maytenusbuchananii L. Africa  Maytansine  --------- 
35 Paris polyphilla 
Trilliaceae 
China --------- Polyphyllin 
36 Pestemondeustus 
Serophulariaceae 
U.S.A Liriodendrin Lignan 
37 Phaleriamacrocarpa 
Thymelaeaceae 
Indonesia Pinoresinol, 
Laricinesinol 
Lignan 
38 Podophyllumemodii 
Berberidaceae 
India Epi-podophyllotoxin Alkaloid 
39 Podophyllumpeltatum L. 
Berberidaceae 
U.S.A. Podophyllotoxin 
 
Glycoside 
40 Polygonumcuspidatum 
Polygonaceae 
Japan, China Resveratrol Flavanoid 
41 Pterismultifida 
Pteridaceae 
Japan Pterokaurane Terpenoid 
42 Pygeumafricanum 
Rosaceae 
 
Africa Amygdalin Glycoside 
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1.3 Crinum asiaticum 
 
 
 
Plate 1.1: The plant Crinum asiaticum („tembaga suasa‟ or „bakong‟) 
 
Table 1.1: Continued 
Sr. 
No. 
Plant name /Family Country where 
used 
Active principle Class 
43 Vitexrotundifolia,  
Verbenaceae 
India 
Korea 
Casticin Flavanoid 
44 Wikstroemiaviridi 
Thymelaeaceae 
China Wikstromol Coumarin 
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Plate 1.2: The plant Crinum asiaticum („tembaga suasa‟ or „bakong‟) 
 
1.3.1 General 
Crinum asiaticum, a large, white-flowered, lily-like plant, commonly found along 
sandy sea-shores, and sometimes planted inland, is occasionally cultivated for its beautiful 
and showy flowers. The plant is known through all Malaysia as tembaga suasa, bakong 
(melong), bawang tanah, or bawang hitam. It also grows in India, and can be found on the 
strand from South East Asia to western Polynesia (Quisumbing, 1951). 
 
C. asiaticum has large, coated bulbs, 5 to 10 cm in diameter. The leaves are crowded at the 
apex, lanceolate, 90 to 150 cm long, 12 to 15 cm wide. Its scape, arising from the axils of the 
old leaves, is erect, stout, and solid, 1 m high, or less. The spathe subtending the flowers, is 
about 15 cm long. Its flowers are fragrant, 20 to 40, each subtended by a thin, narrow, 
bracteole. The perianth tube is greenish, and about 1 cm long; and the lobes are spreading, 
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white, linear, recurved or revolute, about 8 cm long, and 8 mm wide. Its filaments are very 
slender, free, and purplish above. The fruits are sub-globose, about 5 cm in diameter. 
The substance acting emetically, was reported to be an alkaloid, lycorine (1 to 1.8 %), which 
is allied to emetine. The astringent property is due to the presence of a considerable quantity 
of tannin (Quisumbing, 1951). 
 
1.3.2 Uses of Crinum asiaticum in traditional medicine 
 The parts of the plant used medicinally, are the leaves and the bulbs, which are 
mentioned in the Pharmacopoeia of India (Quisumbing, 1951). The bulbs are prepared as an 
ointment, and the leaves are used as an emollient, both in the form of topicals. The bulbs 
have emetic properties. The leaves and roots are also emetic and diaphoretic, and considered 
a good substitute for ipecacuanha. Moreover, they act without gripping, purging, or any other 
distressing symptoms. The succulent leaves, besmeared with castor oil, and warmed, or the 
bruised leaves, mixed with the oil, form a useful application for repelling witlows, and other 
inflammations at the ends of toes and fingers; also as formentations on inflamed joints and 
sprains. Another use of the leaves (juice with a little salt) is for earache, and other ear 
complaints. After being slightly heated, an oil is also prepared from the fresh juice, and used 
for the same purposes. 
According to The Indian Materia Medica (Quisumbing, 1951), the roasted bulb is used as a 
rubefacient in rheumatism. The bulbs also have been used in India, as tonics, laxatives and 
expectorants, and in urinary troubles, whilst the seeds are applied for purgatives and diuretic 
actions. The leaves are also used as expectorants, and against skin diseases (Patel et. al., 
2010). 
Crinum asiaticum does not appear to be used as an internal medicine by the Malays. In 
Malaysian state of Pahang, the Malays oil the long smooth leaves of „bakong‟ and, after 
